Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a positive performance with a 1.02% increase in value and significant trading volume, indicating strong investor interest in the innovative drug sector [1] Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) recorded a trading volume of 1.338 billion yuan on August 21 [1] - The fund's total shares increased by 43 million, bringing the total to 6.167 billion shares, with a notable increase of 3.974 billion shares over the past 20 trading days [1] - The latest net asset value of the fund is 6.094 billion yuan [1] Group 2: Benchmark and Management - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] - The fund is managed by Yinhua Fund Management Co., Ltd., with Ma Jun as the fund manager [1] Group 3: Returns - Since its establishment on January 3, 2024, the fund has achieved a return of 97.64% [1] - Over the past month, the fund has delivered a return of 10.59% [1]
8月21日港股创新药ETF（159567）份额增加4300.00万份，最新份额61.67亿份，最新规模60.94亿元
Xin Lang Cai Jing·2025-08-22 01:12